131 related articles for article (PubMed ID: 15727931)
21. Increased expression of MUC18 correlates with the metastatic progression of mouse prostate adenocarcinoma in the TRAMP model.
Wu GJ; Fu P; Chiang CF; Huss WJ; Greenberg NM; Wu MW
J Urol; 2005 May; 173(5):1778-83. PubMed ID: 15821586
[TBL] [Abstract][Full Text] [Related]
22. Non-invasive bioluminescent detection of prostate cancer growth and metastasis in a bigenic transgenic mouse model.
Hsieh CL; Xie Z; Yu J; Martin WD; Datta MW; Wu GJ; Chung LW
Prostate; 2007 May; 67(7):685-91. PubMed ID: 17342752
[TBL] [Abstract][Full Text] [Related]
23. Malignancy arising in seminal vesicles in the transgenic adenocarcinoma of mouse prostate (TRAMP) model.
Yeh IT; Reddick RL; Kumar AP
Prostate; 2009 May; 69(7):755-60. PubMed ID: 19170049
[TBL] [Abstract][Full Text] [Related]
24. Comparative pathology of benign prostatic hyperplasia and prostate cancer.
Maini A; Archer C; Wang CY; Haas GP
In Vivo; 1997; 11(4):293-9. PubMed ID: 9292295
[TBL] [Abstract][Full Text] [Related]
25. Longitudinal cohort analysis of lethal prostate cancer progression in transgenic mice.
Hsu CX; Ross BD; Chrisp CE; Derrow SZ; Charles LG; Pienta KJ; Greenberg NM; Zeng Z; Sanda MG
J Urol; 1998 Oct; 160(4):1500-5. PubMed ID: 9751403
[TBL] [Abstract][Full Text] [Related]
26. Context-dependent hormone-refractory progression revealed through characterization of a novel murine prostate cancer cell line.
Watson PA; Ellwood-Yen K; King JC; Wongvipat J; Lebeau MM; Sawyers CL
Cancer Res; 2005 Dec; 65(24):11565-71. PubMed ID: 16357166
[TBL] [Abstract][Full Text] [Related]
27. Decreased NKX3.1 protein expression in focal prostatic atrophy, prostatic intraepithelial neoplasia, and adenocarcinoma: association with gleason score and chromosome 8p deletion.
Bethel CR; Faith D; Li X; Guan B; Hicks JL; Lan F; Jenkins RB; Bieberich CJ; De Marzo AM
Cancer Res; 2006 Nov; 66(22):10683-90. PubMed ID: 17108105
[TBL] [Abstract][Full Text] [Related]
28. Minimum altered regions in early prostate cancer progression identified by high resolution whole genome tiling path BAC array comparative hybridization.
Watson SK; Woolcock BW; Fee JN; Bainbridge TC; Webber D; Kinahan TJ; Lam WL; Vielkind JR
Prostate; 2009 Jun; 69(9):961-75. PubMed ID: 19267368
[TBL] [Abstract][Full Text] [Related]
29. The role of P501S and PSA in the diagnosis of metastatic adenocarcinoma of the prostate.
Sheridan T; Herawi M; Epstein JI; Illei PB
Am J Surg Pathol; 2007 Sep; 31(9):1351-5. PubMed ID: 17721190
[TBL] [Abstract][Full Text] [Related]
30. HMGA2 expression in a canine model of prostate cancer.
Winkler S; Murua Escobar H; Meyer B; Simon D; Eberle N; Baumgartner W; Loeschke S; Nolte I; Bullerdiek J
Cancer Genet Cytogenet; 2007 Sep; 177(2):98-102. PubMed ID: 17854662
[TBL] [Abstract][Full Text] [Related]
31. Valproic acid induces neuroendocrine differentiation and UGT2B7 up-regulation in human prostate carcinoma cell line.
Valentini A; Biancolella M; Amati F; Gravina P; Miano R; Chillemi G; Farcomeni A; Bueno S; Vespasiani G; Desideri A; Federici G; Novelli G; Bernardini S
Drug Metab Dispos; 2007 Jun; 35(6):968-72. PubMed ID: 17371798
[TBL] [Abstract][Full Text] [Related]
32. Enforced epithelial expression of IGF-1 causes hyperplastic prostate growth while negative selection is requisite for spontaneous metastogenesis.
Kaplan-Lefko PJ; Sutherland BW; Evangelou AI; Hadsell DL; Barrios RJ; Foster BA; Demayo F; Greenberg NM
Oncogene; 2008 May; 27(20):2868-76. PubMed ID: 18026134
[TBL] [Abstract][Full Text] [Related]
33. IL-6, IL-10 and HSP-90 expression in tissue microarrays from human prostate cancer assessed by computer-assisted image analysis.
Cardillo MR; Ippoliti F
Anticancer Res; 2006; 26(5A):3409-16. PubMed ID: 17094460
[TBL] [Abstract][Full Text] [Related]
34. The increased expression of periostin during early stages of prostate cancer and advanced stages of cancer stroma.
Tsunoda T; Furusato B; Takashima Y; Ravulapalli S; Dobi A; Srivastava S; McLeod DG; Sesterhenn IA; Ornstein DK; Shirasawa S
Prostate; 2009 Sep; 69(13):1398-403. PubMed ID: 19479898
[TBL] [Abstract][Full Text] [Related]
35. Molecular classification of green tea catechin-sensitive and green tea catechin-resistant prostate cancer in the TRAMP mice model by quantitative real-time PCR gene profiling.
Scaltriti M; Belloni L; Caporali A; Davalli P; Remondini D; Rizzi F; Astancolle S; Corti A; Bettuzzi S
Carcinogenesis; 2006 May; 27(5):1047-53. PubMed ID: 16314398
[TBL] [Abstract][Full Text] [Related]
36. Modeling prostate cancer: a perspective on transgenic mouse models.
Jeet V; Russell PJ; Khatri A
Cancer Metastasis Rev; 2010 Mar; 29(1):123-42. PubMed ID: 20143131
[TBL] [Abstract][Full Text] [Related]
37. Modeling human prostate cancer in genetically engineered mice.
Wang F
Prog Mol Biol Transl Sci; 2011; 100():1-49. PubMed ID: 21377623
[TBL] [Abstract][Full Text] [Related]
38. High-resolution array CGH identifies novel regions of genomic alteration in intermediate-risk prostate cancer.
Ishkanian AS; Mallof CA; Ho J; Meng A; Albert M; Syed A; van der Kwast T; Milosevic M; Yoshimoto M; Squire JA; Lam WL; Bristow RG
Prostate; 2009 Jul; 69(10):1091-100. PubMed ID: 19350549
[TBL] [Abstract][Full Text] [Related]
39. Synergy of p53 and Rb deficiency in a conditional mouse model for metastatic prostate cancer.
Zhou Z; Flesken-Nikitin A; Corney DC; Wang W; Goodrich DW; Roy-Burman P; Nikitin AY
Cancer Res; 2006 Aug; 66(16):7889-98. PubMed ID: 16912162
[TBL] [Abstract][Full Text] [Related]
40. The impact of diet and micronutrient supplements on the expression of neuroendocrine markers in murine Lady transgenic prostate.
Palmer J; Venkateswaran V; Fleshner NE; Klotz LH; Cox ME
Prostate; 2008 Mar; 68(4):345-53. PubMed ID: 18188867
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
